Quick Order Cart

Cat. No. ARG0474

MAPKAPK2 Knockout JEG-3 Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Placenta

  • Disease:

    Choriocarcinoma

  • Gene Species:

    Homo sapiens (Human)

CRISPR/Cas9-edited MAPKAPK2 knockout JEG-3 cell line. JEG-3 is a human choriocarcinoma line serving as a trophoblast model, secreting hCG and forming epithelial barriers. MAPKAPK2, a kinase downstream of p38 MAPK, phosphorylates HSPB1 and ZFP36 to regulate actin dynamics and mRNA stability of pro-inflammatory cytokines. This knockout model facilitates research into inflammatory signaling, post-transcriptional gene regulation, trophoblast function, and cancer cell migration. Key applications include cytokine profiling, mRNA decay assays, wound healing, and drug target validation.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    JEG-3

    Morphology

    Epithelial-like

    Age

    Fetus

    Sex of Donor

    Male

    Gene Name

    MAPKAPK2

    Gene Species

    Homo sapiens (Human)

    Gene Identifier

    NCBI Gene ID 9261

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The MAPKAPK2 Knockout JEG-3 Cell Line is a CRISPR/Cas9-edited knockout cell line for functional studies of MAPKAPK2 in human placental choriocarcinoma cells. Targeted gene disruption in the JEG-3 background creates a stable loss-of-function model to investigate MAPKAPK2-dependent signaling pathways, gene regulation, and cellular stress responses without reliance on transient knockdown methods.

The parental JEG-3 cell line is an adherent epithelial line derived from a trophoblastic tumor, widely used as a model for trophoblast function. It secretes human chorionic gonadotropin (hCG) and forms epithelial barriers, making it suitable for research in placental biology, hormone regulation, and cancer. JEG-3 cells retain features of extravillous trophoblasts, including invasiveness and responsiveness to inflammatory mediators, offering a relevant context for studying signaling networks in reproduction and oncology.

MAPKAPK2 encodes a serine/threonine kinase that acts downstream of p38 MAPK, a central stress-activated kinase. Upon stimulation by TNF-??, IL-1??, or other stress signals, p38 MAPK??activated by MKK3 and MKK6??phosphorylates MAPKAPK2. Active MAPKAPK2 then phosphorylates HSPB1 (Hsp27) to modulate actin cytoskeleton remodeling and ZFP36 (tristetraprolin) to enhance decay of AU-rich element (ARE)-containing mRNAs, including those encoding TNF-?? and IL-6. Additional substrates include CREB, SRF, and EEF2K, and the kinase interacts with scaffold protein JIP2. This pathway integrates environmental cues to coordinate inflammatory gene expression, mRNA stability, and cell motility.

Disruption of MAPKAPK2 in JEG-3 cells allows dissection of its role in trophoblast biology and choriocarcinoma pathogenesis. The knockout model permits analysis of p38-MAPKAPK2-mediated control of hCG secretion, epithelial barrier integrity, and inflammatory gene expression relevant to placental disorders such as preeclampsia. Concurrently, it enables study of tumor cell migration and invasion, as MAPKAPK2 regulates actin dynamics through HSPB1 and cytokine mRNA turnover through ZFP36 in a cell type that naturally expresses these components.

Applications include inflammatory signaling studies using ELISA and RT-qPCR for cytokines, actinomycin D mRNA decay assays, and ARE-luciferase reporters; migration and actin remodeling assessed by wound healing and F-actin immunofluorescence; and stress response profiling via phospho-HSPB1 Western blotting and sensitivity to p38 inhibitors like SB203580. Co-immunoprecipitation and RNA-seq can further define altered protein interactions and transcriptomes. For detailed characterization or technical inquiries, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)